Passage BIO Files 2025 Proxy Statement
Ticker: PASG · Form: DEF 14A · Filed: Apr 16, 2025 · CIK: 1787297
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Passage BIO proxy filed - shareholders vote on directors & company matters May 28.
AI Summary
Passage BIO, Inc. filed its definitive proxy statement on April 16, 2025, for its annual meeting of stockholders on May 28, 2025. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key details regarding director nominations and other corporate matters will be presented.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that details corporate governance and upcoming shareholder votes, not a filing indicating significant new risks or events.
Key Numbers
- 20250528 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250416 — Filing Date (Date the proxy statement was filed with the SEC.)
Key Players & Entities
- Passage BIO, Inc. (company) — Registrant
- 0001787297 (company) — Central Index Key
- 2678660312 (dollar_amount) — Business Phone
- 20250416 (date) — Filing Date
- 20250528 (date) — Meeting Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the annual meeting, including details on director nominations, executive compensation, and other matters to be voted upon.
When is the annual meeting of stockholders for Passage BIO, Inc.?
The annual meeting of stockholders is scheduled for May 28, 2025.
Who is the filer of this proxy statement?
Passage BIO, Inc. is the registrant and filer of this proxy statement.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the SIC code for Passage BIO, Inc.?
The Standard Industrial Classification (SIC) code for Passage BIO, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 16, 2025 regarding Passage BIO, Inc. (PASG).